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TUBULAR CARCINOMA OF THE BREAST VERSUS INVASIVE DUCTAL CARCINOMA TREATED 
WITH BREAST CONSERVATION THERAPY 
Gene-Fu F. Liu, Qifeng Yang, Bruce G. Haffty,, Meena S. Moran. 
Department of Therapeutic Radiology, Yale University, School of Medicine, New Haven, CT. 
Purpose: The purpose of our study is to evaluate our institutional experience of treating Tubular 
Carcinoma of the Breast (TC) and Invasive Ductal Carcinoma (IDC) with Breast Conservation 
Therapy (BCT), consisting of conservative surgery (CS) and radiation therapy (RT), and to 
compare clinical-pathologic features and long-term outcomes.  
Materials and Methods: A review of our institution’s tumor registry from 1975-2007 was 
performed, followed by a central pathology review of available slides, yielding 71 cases of Stage 
I/II TC and 2238 cases of Stage I/II IDC treated with BCT.   
Results: Clinical-pathologic features and outcomes were thn analyzed by subtype to detect 
significant differences.  The median follow-up was 7 years.  The TC cohort presented more 
frequently with pT1 disease (97% vs. 80%, p=0.0007), pN0 disease (95% vs. 74%, p=0.0004), 
hormone-receptor positivity (ER+:  89% vs. 62%, p=0.00 1; PR+: 81% vs. 52%, p=0.0001), and 
HER-2 negativity (89% vs. 71%, p= 0.04).  Clinical outcomes also favored the TC cohort, with 
lower rates of breast cancer-related death (1% vs. 10%; p = 0.0109) and distant metastasis (1% 
vs. 13%; p = 0.0028), and higher rates of 10-year ove all (90% vs. 80%; p=0.033), cause-specific 
(99% vs. 86%; p=0.011), and disease-free (99% vs. 82%; p=0.003) survival.  There was a non-
significant trend towards improved breast relapse-fre  survival for the TC cohort (95% vs. 87%; 
p=0.062) but no difference in nodal relapse-free survival or contralateral breast relapse-free 
survival (all p-values > 0.05) between the cohorts.   
Conclusion: Our institutional experience suggests that TC, when compared to IDC, is associated 
with more favorable clinical-pathologic features and comparable, if not superior, outcomes 
following BCT, suggesting the appropriateness of a conservative approach to this rare subtype.   
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Breast conservation therapy (BCT), consisting of a wide excision of the primary 
breast lesion and loco-regional radiotherapy (RT), has been demonstrated in multiple 
randomized trials to be equivalent to mastectomy with regards to disease-free survival 
(DFS) and overall survival (OS) in the treatment of early stage breast cancer.1,2   
However, these reports have not stratified patients by ubtype and were mostly comprised 
of patients with invasive ductal carcinoma (IDC), which constitute approximately 68-
79%. of invasive breast cancer histologies.3-5 Few studies have analyzed the outcomes of 
BCT on less prevalent histologies of the disease.  Tubular carcinoma (TC) is one such 
subtype, comprising approximately only 1% of all invasive breast cancers.3,4  
Table 1. Demographic characteristics of 139,310 women  
diagnosed with nine different histologic types of breast cancer 
Histology n Percent 
Invasive Ductal 102,463 73.6% 
Invasive Lobular 11,275 8.1% 
Ductal/Lobular 9,636 6.9% 
Mucinous 3,248 2.3% 
Comedo 2,222 1.6% 
Inflammatory 2,095 1.5% 
Tubular 1,983 1.4% 
Medullary 1,617 1.2% 
Papillary 618 0.4% 
Table taken from Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast 




 Once termed the “well-differentiated carcinoma of the breast” or “orderly 
carcinoma of the breast,”6 TC can appear merely as benign tubules on microscopic 
examination.  Though its histopathologic definition has evolved over time, it currently 
consists of three main characteristics: 1.) Well-differentiated tubules in a stellate 
infiltrating configuration, 2.) Bland epithelium with non-pleomorphic nuclei, and 3.) 
Myoepithelial cells absent on immunohistochemical st ining.7 
The first characteristic is the presence of well-differentiated tubules, with a 
stellate infiltrating configuration,7 i.e., the tubules radiate outward through normal 
mammary tissue.  In addition, TC characteristically incites a fibrous reaction and thus is 
typically surrounded by a reactive fibrous stroma on microscopic exam.8 Though the 
tubules often contain secretory material and cellular debris, they remain widely patent, 
helping to differentiate TC from other lesions featuring obliterated tubules and ducts, e.g., 
sclerosing adenosis.9 Finally, the tubules are often angular in conformation, and their 
pointed ends are referred to as “prows,” as they resemble the front of a ship or boat.10  
The minimal percentage of tumor cells forming tubules—also known as 
“tubularity”—required to diagnose a TC has evolved in the literature.  Initially, 
pathologists established 90% as the minimal tubularity required. Such lesions merited the 
diagnosis of a “pure” TC.   Correspondingly, lesions between 75-90% tubular histology 
were labeled “mixed TC.”11 The cutoff of 75% has been established to hold clinical 
significance in numerous studies, including one by Carstens et al., which reported that 
patients with lesions of 50-75% tubularity shared survival outcomes similar to IDC at 20 
years (p>0.998).  In contrast, there was a highly significant difference in Kaplan-Meier 
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survival curves between a cohort of IDC versus a cohort of mixed and pure TC cases (p 
<0.001).12   
Currently, however, the distinction between mixed and pure TC is considered 
unnecessary, as their prognostic equivalency has been established by several studies. In 
particular, a large review by Peters, et al. of 100 cases, demonstrated the association 
between percent tubular histology and tumor aggressiv ness.13 In the review, there was 
no difference in the incidences of local recurrence, distant metastasis, or death from 
breast cancer between cases of mixed and pure TC.  In contrast, patients with lesions 
with less than 75 percent tubular histology suffered proportionally worse rates of the 
aforementioned clinical parameters, in addition to larger mean tumor size (Table 2).    
Table 2. Comparative Features of Carcinomas  














100 16 1.79 0 0 0 
76-99 20 2.15 0 0 0 
51-75 16 2.01 6 31 0 
31-50 23 2.50 4 48 17 
5-30 22 2.54 4 25 4 
Figure taken from Peters GN, Wolff M, Haagensen CD.  Tubular carcinoma of the breast.  
Clinical pathologic correlations based on 100 cases.  Ann Surg 1981; 193: 138-149. 
 
Of note, the 75% cutoff does not apply to lesions of mixed tubular and cribriform 
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carcinoma histology.  In these cases, the diagnosis is that of the dominant histology found 
in greater than 50% of the lesion because both cribriform and tubular lesions share 
excellent prognoses.  However, the same classification criteria does not apply to mixed 
tubular and lobular lesions, as described in greate detail below. 
In addition to the presence of well-defined tubules, the second diagnostic criteria 
of TC is a lack of nuclear pleomorphism,14 and more than 90% of the cells must feature 
nuclear grade I, as codified by various nuclear grading systems, e.g., Bloom-Richardson 
or Nottingham, from grades 1 to 3.7  Grade I nuclei are devoid of condensed chromatin, 
prominent nucleoli, and frequent mitotic figures, and the presence of such pleomorphism 
in a TC is highly unusual; its presence should prompt a search for an alternative histologic 
diagnosis. In addition to low-grade nuclei, the tumor cells themselves are also well-
differentiated, being uniform in conformation, eithr normal or moderately enlarged in 
size, and arranged in a single epithelial layer.7   
However, the presence of tubules and a single-layer of bland epithelium are not 
pathognomonic findings.  Indeed, the aforementioned d scription also depicts the 
histology belonging to normal breast tissue or benign sclerosing lesions, such as 
sclerosing adenosis.15 At this juncture in the differential diagnosis, the delimiting factor is 
the third characteristic of a TC: the presence or absence of a myoepithelial cell layer, the 
lack of which is a feature shared amongst all invasive breast cancers.  Myoepthelial cells 
are detected via immunohistochemical staining against a variety of markers (Table 3) and 
their absence confirms the invasive nature of a lesion.  Their presence supports an in situ 
process.7 
Table 3. Immunohistologic Markers of Myoepithelial Cells 
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Marker Sensitivity Specificity 
Calponin Excellent Very good 
p63 Excellent Excellent 
Smooth muscle myosin heavy 
chain 
Good Excellent 
CD10 (CALLA) Good Good 
High molecular weight 
cytokeratin 
Very good Poor 
Maspin Good Poor 
S100 Good Very poor 
Actin Good Very poor 
Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular 




 TC is frequently associated with foci of ductal carcinoma in situ (DCIS).  
Historically, the relationship between the lesions was cited so often in the literature 
(Table 4) that many postulated that TC was an intermediate histology between DCIS and 
IDC. 
Table 4. Frequency of Associated Intraductal Disease  
Observed in Tubular Carcinoma 
Study No. of Patients No. with DCIS (%) 
Deos6  145 99 (68%) 
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Winchester16  50 16 (32%) 
Cabral17 44 23 (52%) 
Oberman18 25 21 (84%) 
McBoyle19  22 14 (64%) 
Total 286 173 (60%) 
Abbreviations: DCIS = ductal carcinoma in situ 
 
Differential Diagnosis 
The well-differentiated histopathology of TC dictates that lesions graded as II or 
III in overall histology (by various grading systems) are not tubular by definition.7 As 
another consequence of its appearance, TC can be readily misclassified as benign lesions, 
e.g., sclerosing adenosis, microglandular adenosis, tubular adenosis, radial scar, and thus 
demands adequate tissue examination when its diagnosis is suspected.   At a minimum, a 
core-needle biopsy is required, as examination with fine-needle aspiration cytology is 
associated with a high false negative rate.20,21 
Even with adequate tissue, however, differentiating TC from other lesions can be 
difficult.  One such challenge is the important distinction between TC, an invasive breast 
cancer, and sclerosing adenosis, a benign subtype of mammary hyperplasia, as both 
growths feature tubular formation and benign appearing epithelium.  The comparative 
ultrastructure only has subtle, non-specific differences (Table 5).  TCs feature tubules 
with a stellate, infiltrating pattern, patent ducts, minimal branching, and a single layer of 
cells.  In contrast, sclerosing adenosis has tubules with a circumscribed and nodular 
pattern, obliterated lumens, frequent branching, and occasional regions of multi-layered 
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epithelium.  As stated above, the crucial difference is the presence or absence of 
myoepithelium as detected by immunohistochemistry. 
Table 5. Comparative Ultrastructure of Tubular Carcinoma  
Versus Sclerosing Adenosis 
Tubular Carcinoma Sclerosing Adenosis 
Stellate infiltrating pattern Circumscribed, nodular 
Patent ducts, gaping lumens Occasional obliterated ducts 
Minimal branching Frequent branching 
Single layer of cells Occasional multi-layered epithelium 
Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular 
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>. 
Accessed, 2008. 
 
 Another important distinction is differentiating TC versus tubulo-lobular 
carcinoma, with the latter carrying a worse prognosis between that of tubular and 
infiltrating lobular carcinoma.22 In this differential, the percentage of tumor cells 
organized into tubules is the defining factor (Table 6).  If greater than 90% of the lesion 
features tubules, then it is termed a TC.  But if greater than 10% of the lesion has lobular 
carcinomatous feautures, then it is considered a tubulolobular carcinoma.  Of note, 
molecular staining against E-cadherin typically yields positive findings for both lesions.23   
Table 6. Comparative Ultrastructure of Tubular Carcinoma  
Versus Sclerosing Adenosis 
Tubular Carcinoma   Sclerosing Adenosis 
90% pure tubular pattern  Mixed tubular and lobular p tterns 
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Stellate infiltrating architecture  Linear infiltraive pattern, frequently 
concentric  
Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular 
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>. 
Accessed, 2008. 
 
 Of less importance is the distinction between TC and  small, well-differentiated, 
low-grade IDC.  Though there are differences in the ultrastructure of both (Table 7), a 
small, low-grade, well-differentiated infiltrating ductal carcinoma probably carries such 
an excellent prognosis that the prognostic information gained in such a distinction is 
minimal.7   
Table 7. Comparative Ultrastructure of Tubular Carcinoma  
Versus Grade I Infiltrating Ductal Carcinoma 
Tubular Carcinoma   Grade I Infiltrating Ductal Carcinoma, NOS 
Stellate infiltration  Irregular infiltration 
90% tubules  May have >10% ribbons or cords 
Infrequent branching  Frequent budding and branching 
Single layer of cells  May show stratification 
Uniform chromatin  Slightly irregular chromatin 
Nucleoli inconspicuous  Nucleoli may be prominent 
Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular 





 TC is associated with excellent prognostic features.  First, TC is smaller at 
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presentation than most breast cancer histologies, averaging only 1 cm in largest 
diameter.6,11,13 A recent review of the SEER (Surveilance, Epidemiology, and End 
Results) database reported that 95% of tubular carcinoma presented at a size of 2.0 cm or 
less, compared with 61% of IDC, 42% of medullary carcinoma, and 57% of papillary 
carcinoma.4   
Its small size makes palpation exceedingly difficult and consequently the majority of 
tubular carcinomas, approximately 64-84%, are detect d with the aid of mammographic 
screening.16,19 Of note, TC does not have any unique mammographic or sonographic 
features which differentiate it from other lesions, malignant or benign, 24 and though 
certain features may suggest its diagnosis, the current literature recommends that 
diagnosis should be based solely on histologic examin tion. 
Mammography is so important in the detection of TC that it may have introduced 
artifact to the existing literature.   For instance, though the incidence of TC has steadily 
increased over the past decade (Table 8),3 it has been postulated that the increase is 
merely a byproduct of increased mammographic screening.   
Table 8.  Number of cases of tubular carcinoma by year. 






Table taken from Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast 
cancer. British J Cancer. 2005 Oct 31;93(9):1046-52. 
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This theory is bolstered by the disproportionate percentage of TC in cohorts of patients 
with mammographically-detected breast cancer.  One Australian study noted that TC 
comprised a disproportionate 3.4% of one such cohort.25 Another possible artifact of 
mammographic detection is the high rate of positive family histories of breast cancer 
documented amongst patients with TC. Positive family histories were reported in 40% 
(6/15) in a study by Lagios et al.26 and 33% (13 of 39) in a study by Holland et al.27 
Previous authors have hypothesized that this phenomn is not truly reflective of the 
hereditability of TC.26 Rather, it is argued that patients with TC often have positive 
family histories because those with a family history f breast cancer may be more 
motivated to comply with rigorous mammographic screening and are thus more apt to 
detect smaller lesions.  Nevertheless, other studies have challenged the very notion of an 
increased hereditary component of TC.  Specifically, Claus et al, in a study defining a 
family history to include only first-degree relatives, found TC to have the least 
association with positive family histories among six h stologic breast cancer subtypes.28 
Furthermore, Burki et al. reported that there was no tastical difference in the relative risk 
of breast cancer between first-degree relatives of patients with tubular, invasive ductal, or 
medullary carcinoma.29 
 
Regional Lymph Node Involvement 
In early-stage disease, the regional lymph node status, s determined by axillary 
or sentinel node dissection, is the single most important prognostic factor,30 and patients 
with TC often have negative nodes.  The SEER review cited above reported that cases of 
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TC had positive lymph nodes only 7% of the time, compared with 33% of IDC, 29% of 
medullary carcinoma, and 22% of papillary carcinoma.4 
 
Predictive Features 
 Predictive features predict response to treatment. In breast cancer, the predictive 
features which most influence management are estrogen receptor (ER), progesterone 
receptor (PR), and HER-2 status. 
 
Hormone Receptor Status 
 Patients with cancers expressing ER or PR are candid tes for endocrine 
modulating therapy to prevent estrogen-mediated growth stimulation of cancer cells. 
Such therapy can be accomplished via different strategies in premenopausal and 
postmenopausal women. In premenopausal patients, ovarian ablation, removal, or 
temporary pharmacologic suppression (with gonadotropin releasing hormone analogs, 
e.g., goserelin, leuprolide) are viable options.  Postmenopausal patients have the option of 
inhibiting estrogen production via aromatase inhibitors, such as anastrazole, letrozole, or 
exemestane.  Finally, adjuvant tamoxifen, a selectiv  estrogen receptor modulator 
represents another standard option for women with hormone receptor positive tumors. 
 A recent review of the SEER database reported that 95% of TC are ER positive 
and 81% are PR positive, thus making endocrine regulating therapy a regularly 
prescribed component of TC management. In comparison, only 78% and 67% of IDC are 




The HER2 oncogene encodes for a member of the epidermal growth factor 
receptor family. As a prognostic feature, HER2 over-expression is associated with higher 
rates of disease recurrence and death and influences ch motherapy utilization in such 
patients.31 As a predictive feature, HER2 status is predictive for resistance to systemic 
therapy but also predicts response to trastuzumab or lapatinib, humanized anti-HER2 
monoclonal antibodies.32 Almost all cases of TC are HER2 negative.{Oakley, 2006}  
 
Significance of Prognostic Features  
 A large multi-institutional review of cases of tubular, mucinous, and IDC 
compared features of breast cancer between the thre istologies and found that in 
addition to having a smaller size at presentation and decreased nodal positivity as 
compared to IDC, TC was also more frequently associated with estrogen receptor (ER)-
positivity (91% vs. 82%; p = 0.001), progesterone receptor (PR)-positivity (75% vs. 61%; 
p = 0.001), low S-phase fraction (89% vs. 50%;p = 0.001), and diploid DNA ploidy (81% 
vs. 44%; p =0.05).    
 Interestingly, however, none of these traditional prognostic features influenced 
clinical outcomes for cases of TC in the study.  Univariate and multivariate analyses of 
disease-free survival for TC (n=277, 14 events) demonstrated that neither tumor size, 
nodal status, ER status, PR status, nor S-phase fraction correlated with disease-free 
survival.  In addition, previous small, single-institution studies of TC also suggest that 
nodal spread is not associated with worse prognosis,16,33,34 making this cancer distinct 
from the majority of breast cancer histologies.  One of the only features of TC 
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demonstrated to correlate with a clinical parameter is lymphovascular invasion; in a 
single-institution Italian study of 307 patients, lymphovascular invasion correlated with 
loco-regional recurrence (p=0.001).35  
  
Treatment 
Because of the rarity of TC, there is insufficient data to determine the extent of 
treatment necessary for this uncommon lesion.  It is currently treated as a favorable, 
early-stage breast cancer. 
 
Systemic Therapy 
Due to the rarity of the disease, the role of systemic chemotherapy in the 
treatment of TC has not been firmly established.  Though one study by Kitchen, et al. of 
85 cases reported an 85% decrease in risk of death for patients receiving more than one 
course of chemotherapy,33 another larger study by Diab et al. reported that of 277 
patients, chemotherapy did not correlate with disease-free survival (p = 0.73).36  
Consequently, the current National Comprehensive Cancer Network (NCCN) only 
recommends the use of chemotherapy for ER- and PR-negative tubular lesions greater 
than three centimeters in size or with positive regional nodal metastasis, which is a higher 
threshold than that prescribed for invasive ductal lesions.37 
 Likewise, the role of endocrine therapy is equally uncertain.  Despite the high 
percentage of ER-positivity in tubular lesions, most studies do not demonstrate a survival 
benefit or reduction in local failure.  In particular, Diab et al., reported that of 277 
patients, adjuvant endocrine therapy did not correlate with disease-free survival (p = 
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0.16), 36 and in 48 ER-positive patients, Sullivan, et al. reported no decrease in risk of 
local failure in 24 patients receiving tamoxifen.38 Therefore, the NCCN also advocates 
for a higher threshold for the usage of tamoxifen than is prescribed for IDC. 37  
 
Breast Conservation Therapy 
As an early stage breast cancer, cases of TC are typicall  eligible for breast 
conservation therapy (BCT), which is defined as a wide local excision of the tumor with 
negative margins—accomplished with either lumpectomy, segmental mastectomy, or 
excisional or incisional biopsy—combined with post-perative radiation therapy.  But 
prior to discussing BCT as it pertains to TC, an introduction to this relatively modern 
approach is appropriate. 
   Though surgery remains integral to the management of patients with early-stage 
breast cancer, the efficacy of post-operative radiotherapy introduced the notion of 
providing select patients with a less aggressive alternative to mastectomy.  Now after 
numerous randomized control trials worldwide, the clini al equivalency of mastectomy 
and BCT has been firmly established with regards to survival.  In particular, two 
landmark trials by Fisher, et al. and Veronesi, et al., randomizing patients to either breast 
conserving surgery plus radiation versus mastectomy now have 20 years of follow up 
data and have demonstrated the long-term DFS and OS rates to be equivalent in both 
mastectomy and BCT cohorts. 1,2  
In the Veronesi trial, the rate of death from all cuses was 41.7% in the breast 
conservation arm and 41.2% in the mastectomy arm (p = 1.0) at 20 years; the rates of 
breast-cancer related death was 26.1% in the BCT arm and 24.3% in the mastectomy arm 
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(p = 0.8).  However, 30 women in the BCT cohort hadan ipsilateral breast recurrence, in 
contrast to 8 women in the mastectomy cohort (p <0.001), which provides a crude local 
recurrence rate of 8.8% vs. 2.3%.  However, there were no significant differences in rates 
of contralateral breast carcinomas, distant metastase , or second primary cancers.  
The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial 
conducted by Fisher et al. reported similar results to the Veronesi trial at 20 years, with 
no significant differences observed with respect to disease-free survival, distant-disease-
free survival, or overall survival among patients randomized to BCT or mastectomy. In 
addition, the hazard ratio for death among the BCT cohort, as compared with the 
mastectomy cohort, was 0.97 (95 percent confidence interval, 0.83 to 1.14; P=0.74). 
Therefore despite an increase in local failure rate, BCT has largely been established as 
the treatment of choice for early stage breast cancers in regards to survival and cosmesis. 
Unfortunately, rare breast cancer subtypes lack sufficient patients to conduct large 
single-institution studies or randomized trials to determine the adequacy of BCT in their 
treatment.  However, studies by Vo, et al.,39 Weiss, et al.,40 and Thurman, et al.41 
evaluated the outcomes of BCT for these uncommon subtypes in comparison to those of 
IDC.   In the study by Vo, et al., 1,643 patients formed the study population and consisted 
of 61 cases of mucinous carcinomas, 37 cases of medullary carcinomas, 60 cases of TC, 
and 1,485 cases of IDC.   Amongst the groups, no statistically significant differences 
were found in the local failure rate after a 10.6-year median follow-up, suggesting the 
adequacy of BCT in their treatment. Of note, patients with TC had better 5- and 10-year 
OS rates (p = .013) than the three other histologies.  A study by Thurman, et al. of 20 
cases of mucinous carcinoma, 27 cases of medullary, 28 cases of TC, and 1055 cases of 
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IDC found similar results.  After a 10 year follow-up period, a lower long-term rate of 
DFS was observed in the IDC cohort, though this was not significantly different than that 
of the other subtypes.  A third study by Weiss, et al. comparing the same subtypes 
reported similar results.40    
  
Benefit of Radiation 
The NSABP trial described above also featured a third cohort of women treated 
with lumpectomy alone, which demonstrated the utility of radiotherapy.  These women 
suffered a cumulative incidence of ipsilateral breast recurrence of 39.2%, as compared 
with 14.3% in women undergoing lumpectomy and post-operative irradiation at 20 year 
follow-up (p < 0.001). The hazard ratio for death among the cohort receiving 
lumpectomy alone, as compared with the mastectomy cohort, was 1.05 (95 percent 
confidence interval, 0.90 to 1.23; P=0.51). Treatment by lumpectomy alone has been 
demonstrated in numerous randomized trials to be associated with a three-fold increase in 
local failure (Table 9).42-45   Though individual trials did not report differences in 
survival, two recent metanalyses report a small, but statistically significant compromise 
in survival of 5.3% and 8.6% by omission of radiation.42,46,47   
Table 9. Randomized Trials of Breast-Conserving Therapy  
With or Without Radiation 
                                                                                         Rates of L cal Relapse 
Study n Follow-up Radiotherapy No Radiotherapy 
Fisher et al.43 930 10 years 12.4% 40.9% 
Liljegren et al.44 381 10 years 8.5% 24% 
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Veronesi et al.2 567 10 years 5.83% 23.5% 
Clarke et al.47 837 3 years 5.5% 25.7% 
Winzer et al.45 347 5.9 years 3.2% 27.8% 
Table taken from Haffty B, Wilson, LD. Handbook of Radiation Oncology: Basic Principles and Clinical 
Protocols. First ed: Jones and Bartlett Publishers, 2008:797. 
 
 Just as the adequacy of BCT in the treatment of TC has not been established, few 
have addressed the precise role of radiation in the treatment of TC.  A study by Leonard, 
et al. of 44 patients with pure TC treated only by wide local excision reported a crude 
local failure rate of 96% (2/44), 5- and 10-year local control rates of 100% and 87%, and 
actuarial 5- and 10-year OS and DFS rates of 80% and 52%, and 100% and 91%.48  It 
should be noted, however, that the patients in this study had lesions of pure tubular 
histology and a median tumor size of only 6.5mm (range 2-30 mm).  Further, the median 
age was 67 years (range 40-96 years).  Therefore, this retrospective study suggests that 
breast irradiation might be omitted after conservative surgery in older patients with small 
TC. 
 However, a literature review by Sullivan, et al. suggests that radiation may still 
provide a benefit in local control to patients with TC.  
Table 10. Literature Review of Conservatively Treated  
Cases of Tubular Carcinoma  
 Conservative surgery 
Without Radiotherapy 
Conservative surgery  
With Radiotherapy 
Follow-up 











Tobon et al.49 0 2 0 1 23-month mean 
Carstens12 2 5 - - 24-month mean 
Oberman et 
al.18  
2 2 - - 67-month mean 
Peters et al.13 0 1 0 2 74-month mean 
Deos et al.6 3 8 - - 144-month mean 
McDivitt 8 1 12 0 3 36-month mean 
Weiss et al.40  - - 2 18 61-month median 
Winchester et 
al.16 
0 5 0 16 58-month median 
Schnitt et al.50 0 7 - - 56-month median 
Haffty et al.51  - - 0 21 113-month median 
Bradford et 
al.52 
0 17 0 21 48-month median 
Kitchen et 
al.33 
0 5 0 22 144-month median 
Holland et 
al.27 
2 6 0 23 34.5-month median 
Cabral et al.17 1 21 0 13 58-month mean 
Thurman et 
al.41 
- - 2 28 120-month 
minimum 
Livi et al.35 2 52 8 218 101-month  median 
Sullivan et 0 13 3 49 93-month median 
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al.38 
Total 13 156 15 435  
  8.3%  3.4%  
Table from Sullivan T, Raad RA, Goldberg S, Assaad SI, Gadd M, Smith BL, Powell SN, Taghian AG. 
Tubular carcinoma of the breast: a retrospective analysis and review of the literature.  Breast Cancer 
Research and Treatment. 93: 199-205, 2005. 
 
Future of Breast Conservation Therapy  
 Two recent randomized trials have questioned the need for radiation therapy in 
elderly women.  A study by Hughes, et al. randomized patients over 70 years of age with 
early-stage, node-negative, ER-positive breast cancer to either radiotherapy and 
tamoxifen or tamoxifen alone.53  At five years, radiotherapy significantly lowered local 
failure rates, when compared to the tamoxifen alone group (1% vs. 4%, p <0.001), but 
there were no significant differences between the two groups with regard to the rates of 
mastectomy for local recurrence, distant metastases, or overall survival (87% vs. 86%, p 
= 0.94).  In comparison, a study by Fyles, et al. of patients greater than 50 years of age 
also demonstrated no significant differences in the rat s of distant metastasis or overall 
survival.54  However, the five-year disease-free survival rates (84% vs. 91%; p = 0.004) 
and local relapse rates (7.7% vs. 0.6%, p <0.001) favored the radiation cohort.  Longer 
follow-up data for both studies is awaited.  
 Another potential development in BCT is the use of partial breast irradiation 
following lumpectomy.  For patients with low-risk disease, this approach allows for less 
radiation to be delivered over a shorter course to a restricted breast volume.  The 
radiation can be delivered utilizing a variety of techniques including multiplane 
interstitial catheters, Mammosite-brand balloon, or external beam conformal therapy.   
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The efficacy and safety of partial breast irradiation is currently being studied in an 
ongoing randomized trial, as compared to traditional BCT.   
 
Breast Conservation Therapy in the Treatment of Tubular Carcinoma 
Despite its benign histopathologic characteristics, however, TC has been observed 
to have features which are potentially incompatible with a conservative approach to local 
therapy.  In particular, numerous studies have documented an increased frequency of 
multi-centricity and synchronous or metachronous contralateral disease.16,26,27 These 
characteristics may indicate an increased risk of local recurrence or second primary and 
demand a more aggressive means of local therapy. 
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STATEMENT OF PURPOSE 
The purpose of our investigation was to identify patients with TC treated with 
BCT at our institution.  Like studies by Vo, et al.39 Weiss, et al.,40  and Thurman, et al.41 
discussed above, we aim to elucidate the role of BCT for the treatment of TC by 
comparing the clinical-pathologic features and long-term outcomes of patients with TC to 
those of our large cohort of patients with IDC.  Our hypothesis is that patients with TC 
will have more favorable pre-treatment clinical-pathologic characteristics than those of 




MATERIALS AND METHODS 
Prior to initiating this study, institutional review board (IRB) approval was 
obtained by Dr. Meena Moran to review hospital charts and pathology slides.  From 
tumor registry data, a list of all tubular breast can er cases treated at the facilities of Yale 
University School of Medicine was compiled by Gene-Fu Liu (GFL) with the aid of the 
Yale Tumor Registry and was referenced against a list compiled by Drs. Bruce G. Haffty 
(BGH) and Meena S. Moran (MSM). To identify which of these TC patients were treated 
with BCT, medical chart reviews were conducted by GFL. 
Our study cohort was therefore comprised of Stage I/II TC patients who all 
received conservative surgery and radiation therapy.  Patients with TC who had pathology 
slides available for review underwent central pathology review.  Slides were read by a 
single breast pathologist, Dr. Qifeng Yang (QY), at the Pathology Department of Yale 
New Haven Hospital. Tubular histology was designated to any cases that had greater than 
75% tubular histology as designated by the Stanford Surgical Pathology Criteria.7 
Patients with lesions comprised of less than 75% tubular histology were excluded from 
the TC cohort; as stated above, such lesions have been demonstrated to exhibit a natural 
history similar to that of IDC.12,13 Our comparison cohort consisted of 2238 patients with
Stage I or II invasive ductal histology treated with BCT, identified from our departmental 
breast cancer database, which was compiled by BGH and MSM.  Chart reviews from the 
Departments of Therapeutic Radiology of Yale University were conducted by GFL to 
gather clinical, pathologic and outcomes data on the tubular cohort, and the relevant 
information was entered into our database for analysis.  Data on the invasive ductal 
cohort was collected previously by BGH and MSM.  
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  All patients analyzed in this study were treated with conservative surgery and 
radiation therapy. Conservative surgery consisted of excisional biopsy, lumpectomy, 
quadrantectomy or partial mastectomy, with or without re-excision, to attempt to achieve 
negative surgical margins.  Whole breast RT was deliver d to a median dose of 48 Gy 
using standard tangential techniques, and all patients received a conedown/boost field.  
The boost was delivered in the majority of patients using an en-face electron field which 
was designed to encompass the surgical scar plus a generous margin. The total median 
dose (including cone-down) for both cohorts was 64 Gy.  Regional nodal radiation was 
delivered as previously described.55 Systemic therapy was delivered at the discretion of 
the treating oncologist.  Patients who received neoadjuvant chemotherapy were excluded 
from analysis.  All clinical and pathologic variables of the 2 cohorts were statistically 
analyzed using SAS, Version 9.1 (SAS Institute, Cary, NC).  All tests of statistical 
significance were 2-sided and significance was defined as a p value less than 0.05. 
Bivariate analysis for the association between co-variables and histology were performed 
using chi2 analysis and the Fisher’s exact test.  Outcome parameters were defined as 
follows:  breast recurrence free survival:  time of diagnosis to time of local failure within 
breast; nodal recurrence free survival:  time of diagnosis to time of relapse in the axilla, 
supraclavicular fossa or internal mammary nodes; distant metastasis free survival:  time 
of diagnosis to disease failure outside of the local-regional area.  All events were 
calculated using standard life table methods and the differences were compared using 




The median follow-up for the two cohorts was 7 years.  Table 11 stratifies the pre-
treatment characteristics of patients by subtype.  
Table 11. Pre-Treatment Characteristics by Subtype 
 Stage I/II Invasive Ductal 
Carcinoma 
Tubular Carcinoma P value 
Age 55.8 yrs (range 20-90) 55.6 yrs (range 35-84) NS 
Detected by 
Mammography  
954/1891 (50%) 51/64 (80%) <0.0001 
T1 Disease 1445/1798 (80.37%) 65/67% (97.01%) 0.0004 
N0 Disease 938/1273 (73.68%) 40/42(95.24%) 0.0016 
ER positivity 943/1530 (61.67%) 42/47 (89.36%) 0.001 
PR positivity 719/1391 (51.69%) 35/43 (81.40%) 0.001 
HER-2 
positivity 
123/422 (29.15%) 3/27 (11.11%) 0.043 
Family history 665/1837 (36.20%) 29/64 (45.31%) NS (0.1366) 
Positive 
margins 




669/2068 (32.35%) 27/66 (40.91%) NS (0.1443) 
Adjuvant 
Chemotherapy 
571/2075 (27.52%) 6/70 (8.57%) 0.0004 
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Abbreviations: NS = not significant 
 
Central Pathology Review 
Forty-seven patients had pathology slides available for review.  Of these, 77% 
(36/47) were confirmed as being of the TC subtype.  11 patients were deemed to have 




The average age at presentation was 55.6 years (range 35-84 years) for TC and 55.8 
years (range 20-90) for IDC, respectively (p=NS).  A significantly greater percentage of 
TC lesions were detected mammographically (80% vs. 50%; p<0.0001).  Of the 64 TC 
patients with known family history, 29 (45%) have a family history of breast cancer 
compared with 36% of the IDC cohort (p=0.14). 
 
Tumor characteristics 
At presentation, the TC cohort was associated with a greater percentage of pathologic 
T1 disease (97% vs. 80%; p=0.0007).  Furthermore, of the 43 TC patients with axillary 
staging (15 by sentinel node biopsy and 25 by axillary node dissection), nodal spread was 
detected in only 2 cases (5%), which is significantly less than the 26% (335/1272) of IDC 
patients with nodal metastases (p = 0.0016).  TC cases lso exhibited increased estrogen 
(ER) and progesterone receptor (PR) expression in comparison to IDC lesions, 89% vs. 
62% (p=0.0001) and 81% vs. 52% (p=0.0001), respectively.  HER-2 status was reported 
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as positive in 11% of the TC cases and 29% of IDC cases (p = 0.04) 
 
Adjuvant systemic therapy 
Following definitive local therapy, adjuvant hormonal therapy was administered in 
approximately equal proportions of TC and IDC cases (41% vs. 32%; p = 0.14).  




Figure 1 shows survival curves by outcome.  At ten y ars, overall survival (90% vs. 
80%; p=0.033), cause-specific survival (98 vs. 86%; p=0.011), disease-free survival (99% 
vs. 82%; p=0.003) all favored the TC cohort.  Though there was a trend towards 
improved breast relapse-free survival for the TC cohort than IDC (95% vs. 87%), this 
difference did not achieve statistical significance (p=0.062).  There was no difference in 
nodal relapse-free survival (100% vs. 97%; p=0.216) and contralateral breast relapse-free 
survival (85% vs. 87%; p=0.868) between the 2 cohorts.   
Table 12. Clinical Outcomes by Subtype 
 Stage I/II Invasive 
Ductal Carcinoma 
Tubular Carcinoma P value 
10-year  
Overall Survival 
80% 90% 0.033 
10-year Cause-
Specific Survival 





87% 95% NS (0.062) 
10-year Disease-
Free Survival 









87% 85% NS (0.868) 




This study compares the clinical-pathologic features and long-term outcomes of a 
relatively large cohort of patients with TC treated with BCT with those of a similarly 
treated cohort of patients with IDC.  Overall, progn stic features and clinical outcomes 
parameters favored the TC cohort.  Specifically, pathologic T and N stages and rates of 
hormone receptor negativity or HER-2 over-expression were higher in the IDC cohort.  In 
regards to outcomes, cause-specific, disease-free, and overall survival also favored 
patients with TC over those with IDC. The excellent ou comes of our TC cohort support 
the adequacy of a conservative approach to the treatment of TC. 
Though these results may be expected from a subtype onc  termed the “well-
differentiated carcinoma of the breast,”26 there have been concerns over the use of BCT 
in regards to two observed features of TC.  First, Lagios et al. reported a 56% rate of 
multicentricity in 17 cases of TC,26  which may suggest a potential for increased risk of 
local recurrence with a conservative therapy.  Second, numerous studies have noted an 
increased incidence of contralateral cancer before, during, or after the initial diagnosis of 
TC, with a review of the literature revealing a 14% incidence of 
metachronous/synchronous contralateral disease (Table 13). 
Table 13. Incidence of Contralateral Invasive Disease  
in Patients with Tubular Carcinoma 
Study No. of Patients No. with Contralateral 
Carcinoma (%) 
Carstens et al.11 
  
42 5 (12%) 
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Cooper et al.34 12 2 (17%) 
Oberman et al.18 25 3 (12%) 
Lagios et al.26 16 6 (38%) 
Peters et al.13 36 3 (8%) 
Deos et al.6 90 9 (10%) 
Winchester et al.16  50 13 (26%) 
Taylor et al.56 33 6 (18%) 
Thurman et al.41 38 3 (8%) 
Günhan-Bilgen et al. 57 32 4 (13%) 
Liu et al. (current study) 71 11 (15%) 
TOTAL 445 65 (15%) 
 
This figure is slightly higher than the 2-11% incidence reported for all subtypes58 and 
may suggest a propensity towards developing a second primary lesion.  The basis of 
increased contralateral disease in TC is unknown, though it had been once been 
postulated to arise from the subtype’s high frequency of intraductal disease.  However, 
this concept was not supported by a subset analysis b  Winchester et al., which did not 
show a correlation between intraductal disease and co tralateral disease in patients with 
TC.16  Also of note, our study does not demonstrate that patients with TC are more likely 
than those with IDC to have had or develop metachronous contralateral breast cancer.     
Our results are consistent with the existing literature addressing TC. The 5-year 
99% DFS and 96% OS exhibited by our TC cohort agree with the clinical outcomes of a 
larger multi-institutional study comparing TC with IDC by Diab et al., which included 
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cases treated with mastectomy,36 as well as with three smaller single-institution studies 
comparing TC to other histologies treated exclusively with BCT by Vo et al39, Weiss, et 
al.,40 and Thurman et al. (Table 14).41 Of note, in our review of the literature, this is the 
largest known single-institution study comparing cases of TC to IDC treated exclusively 
with BCT.  
Table 14. Subsets of Patients with Tubular Carcinoma  
Treated with BCT in Previous Studies 
Study Local Recurrence Rate Follow-up 
Winchester, et al. 16 0/16 (0%) 58 months median 
Sullivan, et al.38 3/49 (6%) 90.5 months median 
Livi, et al.35 8/218 (4%) 100.8 months median 
Cabral, et al.17 0/13 (0%) 55 months mean 
Thurman, et al. 41 2/28 (7%) 10 years, minimum 
Vo, et al.39 8/60 (13%) 10.6 years, median 
Liu, et al. (current study) 4/70 (6%) 84 months median 
Total 15/366 (4%)  
Abbreviations: BCT = breast conservation therapy 
 
However, this study has several weaknesses which merit discussion.  Given the time 
span of nearly 3 decades in which these patients were tr ated, and the fact that a 
significant portion of the patients had surgery elsewhere and were subsequently referred 
to our institution for radiation treatment, the availability of slides for central pathology 
review was limited. Furthermore, of the slides available for review, nearly one-quarter 
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were re-classified by our pathologist as a different histologic subtype due to the stringent 
criteria applied.  Of note, there was no stratification of pure versus mixed TC (defined in 
the literature as consisting of greater than 90% and 75% tubular histology, respectively) 
as previous studies have indicated similar outcomes for both histologies.13,17,59 
Another weakness of our study was the inability to perform multivariate analysis due 
to the relatively small number of patients in the TC cohort, which may also have 
underpowered the study to detect statistically significant differences.  Specifically, it is 
possible that the breast and nodal relapse free survival for the TC may indeed be better 
than for IDC, but our study may have been limited in numbers of patients to detect this 
difference as significant.  Furthermore, this may hve compromised our assessment of 
conventional prognostic and predictive features, e.g., nodal positivity or hormone 
receptor status.  An important question that our stdy did not address was how cases of 
TC fare with BCT versus mastectomy, however, our breast database consists of patients 
treated with only breast conservation, and therefore we are unable to address this 
question.  Finally, the retrospective nature of this study introduces significant bias, with 
respect to patient selection and intrinsic, retrospective data collection.   
Though not directly compared between our two cohorts, an interesting phenomena 
described in the literature is the high percentage of patients with positive family histories 
in patients with tubular histology of breast cancer.  In our study, of the 58 cases in which 
family history was documented, 28 (47%) reported a positive history, which is consistent 
with studies by Lagios et al.26 and Holland et al.27 Though the number of TC cases 
reporting positive histories was not significantly different than that of our IDC patients 
(36%), it is important to note that a large number of patients (22%) from the IDC cohort 
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did not have family history data available for analysis, which potentially confounds this 
analysis. 
In conclusion, patients with TC of the breast treated with BCT have excellent long-
term outcomes that are comparable to, if not more favorable than, those of similarly 
treated patients with IDC. These findings support the routine utilization of BCT for the 
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Figure 1.  Survival curves for Tubular Carcinoma versus Invasive Ductal Carcinoma.   
Solid Line: Invasive Ductal Carcinoma, Broken Line: Tubular Carcinoma 
a.) Overall Survival     b.) Cause-Specific Survival     c.) Disease-Free Survival     d.) Breast 
Relapse-Free Survival     e.) Nodal Relapse-Free Survival     f.) Contralateral Breast Relapse-Free 
Survival 
 
 
 
 
